{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:43:02Z","timestamp":1788385382083,"version":"build-2803163510"},"reference-count":326,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41401-024-01455-w","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:48:58Z","timestamp":1738313338000},"page":"1511-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington\u2019s disease and Prion diseases"],"prefix":"10.1038","volume":"46","author":[{"given":"Abhiyanta","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumojit","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsita","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"1455_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fimmu.2020.00337","volume":"11","author":"O Fatoba","year":"2020","unstructured":"Fatoba O, Ohtake Y, Itokazu T, Yamashita T. Immunotherapies in Huntington\u2019s disease and \u03b1-synucleinopathies. Front Immunol. 2020;11:337.","journal-title":"Front Immunol"},{"key":"1455_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103974","volume":"29","author":"A Mukherjee","year":"2024","unstructured":"Mukherjee A, Biswas S, Roy I. Immunotherapy: an emerging treatment option for neurodegenerative diseases. Drug Discov Today. 2024;29:103974.","journal-title":"Drug Discov Today"},{"key":"1455_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/biom11050767","volume":"11","author":"PB Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves PB, Sodero ACR, Cordeiro Y. Green tea epigallocatechin-3-gallate (EGCG) targeting protein misfolding in drug discovery for neurodegenerative diseases. Biomolecules. 2021;11:767.","journal-title":"Biomolecules"},{"key":"1455_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s13311-020-00853-2","volume":"17","author":"S Kwon","year":"2020","unstructured":"Kwon S, Iba M, Kim C, Masliah E. Immunotherapies for aging-related neurodegenerative diseases\u2014Emerging perspectives and new targets. Neurotherapeutics. 2020;17:935\u201354.","journal-title":"Neurotherapeutics"},{"key":"1455_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2017.12.012","volume":"417","author":"K Banerjee","year":"2018","unstructured":"Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, et al. Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett. 2018;417:35\u201346.","journal-title":"Cancer Lett"},{"key":"1455_CR6","volume-title":"Immunology \u2013 A Novel Facet of Modern Therapeutics","author":"D Kamthe","year":"2020","unstructured":"Kamthe D, Gosavi N, Nikam VS. Immunotherapy in neurodegenerative disorders. Immunology \u2013 A Novel Facet of Modern Therapeutics. 1st ed. Singapore: Springer Nature; 2020.","edition":"1st ed."},{"key":"1455_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104760","volume":"137","author":"AD Schwab","year":"2020","unstructured":"Schwab AD, Thurston MJ, Machhi J, Olson KE, Namminga KL, Gendelman HE, et al. Immunotherapy for Parkinson\u2019s disease. Neurobiol Dis. 2020;137:104760.","journal-title":"Neurobiol Dis"},{"key":"1455_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coche.2017.12.006","volume":"19","author":"L Montoliu-Gaya","year":"2018","unstructured":"Montoliu-Gaya L, Villegas S. Immunotherapy for neurodegenerative diseases: the Alzheimer\u2019s disease paradigm. Curr Opin Chem Eng. 2018;19:59\u201367.","journal-title":"Curr Opin Chem Eng"},{"key":"1455_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03509-0","volume":"9","author":"TA Thibaudeau","year":"2018","unstructured":"Thibaudeau TA, Anderson RT, Smith DM. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat Commun. 2018;9:1097.","journal-title":"Nat Commun"},{"key":"1455_CR10","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","volume":"22","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow K, Morenas-Rodr\u00edguez E, Hong S, Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer\u2019s disease. Lancet Neurol. 2023;22:1048\u201360.","journal-title":"Lancet Neurol"},{"key":"1455_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106080","volume":"122","author":"KP Del Giudice","year":"2024","unstructured":"Del Giudice KP, Cosgaya M, Zaro I, Ravasi V, Santacruz P, Painous C, et al. Anti-alpha synuclein and anti-tau immunotherapies: can a cocktail approach work? Parkinsonism Relat Disord. 2024;122:106080.","journal-title":"Parkinsonism Relat Disord"},{"key":"1455_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s43587-024-00630-2","volume":"4","author":"M Sarazin","year":"2024","unstructured":"Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, et al. The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer\u2019s disease. Nat Aging. 2024;4:761\u201370.","journal-title":"Nat Aging"},{"key":"1455_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1248\/cpb.c24-00069","volume":"72","author":"N Suzuki","year":"2024","unstructured":"Suzuki N, Hatta T, Ito M, Kusakabe KI. Anti-amyloid-\u03b2 antibodies and anti-tau therapies for Alzheimer\u2019s disease: recent advances and perspectives. Chem Pharm Bull. 2024;72:602\u20139.","journal-title":"Chem Pharm Bull"},{"key":"1455_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16:529\u201346.","journal-title":"Nat Rev Neurol"},{"key":"1455_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/brainsci7060067","volume":"7","author":"RA Paoli","year":"2017","unstructured":"Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C, et al. Neuropsychiatric burden in Huntington\u2019s disease. Brain Sci. 2017;7:67.","journal-title":"Brain Sci"},{"key":"1455_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington Collaborative Research Group.","year":"1993","unstructured":"Huntington Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"1455_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","volume":"34","author":"KM Shannon","year":"2020","unstructured":"Shannon KM. Recent advances in the treatment of Huntington\u2019s disease: targeting DNA and RNA. CNS Drugs. 2020;34:219\u201328.","journal-title":"CNS Drugs"},{"key":"1455_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1083\/jcb.200508072","volume":"171","author":"JY Shin","year":"2005","unstructured":"Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol. 2005;171:1001\u201312.","journal-title":"J Cell Biol"},{"key":"1455_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ymthe.2022.01.020","volume":"30","author":"M Alpaugh","year":"2022","unstructured":"Alpaugh M, Masnata M, de Rus Jacquet A, Lepinay E, Denis HL, Saint-Pierre M, et al. Passive immunization against phosphorylated tau improves features of Huntington\u2019s disease pathology. Mol Ther. 2022;30:1500\u201322.","journal-title":"Mol Ther"},{"key":"1455_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/mp.2011.28","volume":"16","author":"D Soulet","year":"2011","unstructured":"Soulet D, Cicchetti F. The role of immunity in Huntington\u2019s disease. Mol Psychiatry. 2011;16:889\u2013902.","journal-title":"Mol Psychiatry"},{"key":"1455_CR21","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain. 2007;130:1759\u201366.","journal-title":"Brain"},{"key":"1455_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med. 2008;205:1869\u201377.","journal-title":"J Exp Med"},{"key":"1455_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nn.3668","volume":"17","author":"A Crotti","year":"2014","unstructured":"Crotti A, Benner C, Kerman BE, Gosselin D, Lagier-Tourenne C, Zuccato C, et al. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014;17:513\u201321.","journal-title":"Nat Neurosci"},{"key":"1455_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ana.24174","volume":"76","author":"F Cicchetti","year":"2014","unstructured":"Cicchetti F, Lacroix S, Cisbani G, Valli\u00e8res N, Saint\u2010Pierre M, St\u2010Amour I, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol. 2014;76:31\u201342.","journal-title":"Ann Neurol"},{"key":"1455_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/cells7060059","volume":"7","author":"BL Tang","year":"2018","unstructured":"Tang BL. Unconventional secretion and intercellular transfer of mutant huntingtin. Cells. 2018;7:59.","journal-title":"Cells"},{"key":"1455_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fnbeh.2014.00135","volume":"8","author":"P Pla","year":"2014","unstructured":"Pla P, Orvoen S, Saudou F, David DJ, Humbert S. Mood disorders in Huntington\u2019s disease: from behavior to cellular and molecular. Front Behav Neurosci. 2014;8:135.","journal-title":"Front Behav Neurosci"},{"key":"1455_CR27","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/brain\/aww021","volume":"139","author":"M Gratuze","year":"2016","unstructured":"Gratuze M, Cisbani G, Cicchetti F, Planel E. Is Huntington\u2019s disease a tauopathy? Brain. 2016;139:1014\u201325.","journal-title":"Brain"},{"key":"1455_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1179069518772380","volume":"12","author":"A Maxan","year":"2018","unstructured":"Maxan A, Cicchetti F. Tau: a common denominator and therapeutic target for neurodegenerative disorders. J Exp Neurosci. 2018;12:1179069518772380.","journal-title":"J Exp Neurosci"},{"key":"1455_CR29","volume":"11","author":"M Masnata","year":"2020","unstructured":"Masnata M, Salem S, de Rus Jacquet A, Anwer M, Cicchetti F. Targeting tau to treat clinical features of Huntington\u2019s disease. Front Neurosci. 2020;11:580732.","journal-title":"Front Neurosci"},{"key":"1455_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron. 2019;101:801\u201319.","journal-title":"Neuron"},{"key":"1455_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1872208313666190208163714","volume":"13","author":"K Singh","year":"2019","unstructured":"Singh K, Roy I. Nucleic acid therapeutics in Huntington\u2019s disease. Recent Pat Biotechnol. 2019;13:187\u2013206.","journal-title":"Recent Pat Biotechnol"},{"key":"1455_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14737175.2019.1631161","volume":"19","author":"H Bashir","year":"2019","unstructured":"Bashir H. Emerging therapies in Huntington\u2019s disease. Expert Rev Neurother. 2019;19:983\u201395.","journal-title":"Expert Rev Neurother"},{"key":"1455_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","volume":"46","author":"W Duan","year":"2023","unstructured":"Duan W, Urani E, Mattson MP. The potential of gene editing for Huntington\u2019s disease. Trends Neurosci. 2023;46:365\u201376.","journal-title":"Trends Neurosci"},{"key":"1455_CR34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium.","year":"2019","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium. CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell. 2019;178:887\u2013900.","journal-title":"Cell"},{"key":"1455_CR35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.89782.2","volume":"12","author":"DE Choi","year":"2024","unstructured":"Choi DE, Shin JW, Zeng S, Hong EP, Jang JH, Loupe JM, et al. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington\u2019s disease. Elife. 2024;12:RP89782.","journal-title":"Elife"},{"key":"1455_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad344","volume":"5","author":"S Regio","year":"2023","unstructured":"Regio S, Vachey G, Go\u00f1i E, Duarte F, Rybarikova M, Sipion M, et al. Revisiting the outcome of adult wild-type HTT inactivation in the context of HTT-lowering strategies for Huntington\u2019s disease. Brain Commun. 2023;5:fcad344.","journal-title":"Brain Commun"},{"key":"1455_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17460441.2021.1829587","volume":"16","author":"S Jain","year":"2021","unstructured":"Jain S, Kaur J, Prasad S, Roy I. Nucleic acid therapeutics: a focus on the development of aptamers. Expert Opin Drug Discov. 2021;16:255\u201374.","journal-title":"Expert Opin Drug Discov"},{"key":"1455_CR38","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/mt.2015.157","volume":"23","author":"RK Chaudhary","year":"2015","unstructured":"Chaudhary RK, Patel KA, Patel MK, Joshi RH, Roy I. Inhibition of aggregation of mutant huntingtin by nucleic acid aptamers in vitro and in a yeast model of Huntington\u2019s disease. Mol Ther. 2015;23:1912\u201326.","journal-title":"Mol Ther"},{"key":"1455_CR39","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1021\/acschemneuro.3c00226","volume":"14","author":"S Jain","year":"2023","unstructured":"Jain S, Roy I. Aptamer reduces aggregation of mutant huntingtin and rescues proteostasis network in non-neuronal and neuronal cells. ACS Chem Neurosci. 2023;14:2385\u201395.","journal-title":"ACS Chem Neurosci"},{"key":"1455_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nm985","volume":"10","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004;10:148\u201354.","journal-title":"Nat Med"},{"key":"1455_CR41","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1021\/acschemneuro.9b00167","volume":"10","author":"V Singh","year":"2019","unstructured":"Singh V, Patel KA, Sharma RK, Patil PR, Joshi AS, Parihar R, et al. Discovery of arginine ethyl ester as polyglutamine aggregation inhibitor: conformational transitioning of huntingtin N-terminus augments aggregation suppression. ACS Chem Neurosci. 2019;10:3969\u201385.","journal-title":"ACS Chem Neurosci"},{"key":"1455_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106049","volume":"122","author":"C Sampaio","year":"2024","unstructured":"Sampaio C. Huntington disease - Update on ongoing therapeutic developments and a look toward the future. Parkinsonism Relat Disord. 2024;122:106049.","journal-title":"Parkinsonism Relat Disord"},{"key":"1455_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd2784","volume":"8","author":"MR Hayden","year":"2009","unstructured":"Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Tetrabenazine. Nat Rev Drug Discov. 2009;8:17\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"1455_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79:597.","journal-title":"Neurology"},{"key":"1455_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RL, Kwakowsky A. Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis. 2022;14:11795735221092517.","journal-title":"J Cent Nerv Syst Dis"},{"key":"1455_CR46","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41380-018-0021-9","volume":"24","author":"HL Denis","year":"2019","unstructured":"Denis HL, Lauruol F, Cicchetti F. Are immunotherapies for Huntington\u2019s disease a realistic option? Mol Psychiatry. 2019;24:364\u201377.","journal-title":"Mol Psychiatry"},{"key":"1455_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd4024","volume":"12","author":"FM Longo","year":"2013","unstructured":"Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12:507\u201325.","journal-title":"Nat Rev Drug Discov"},{"key":"1455_CR48","doi-asserted-by":"publisher","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"DA Simmons","year":"2013","unstructured":"Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. J Neurosci. 2013;33:18712\u201327.","journal-title":"J Neurosci"},{"key":"1455_CR49","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.1093\/hmg\/ddv335","volume":"24","author":"AI Ramsingh","year":"2015","unstructured":"Ramsingh AI, Manley K, Rong Y, Reilly A, Messer A. Transcriptional dysregulation of inflammatory\/immune pathways after active vaccination against Huntington\u2019 s disease. Hum Mol Genet. 2015;24:6186\u201397.","journal-title":"Hum Mol Genet"},{"key":"1455_CR50","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","volume":"7","author":"TW Miller","year":"2003","unstructured":"Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype. Mol Ther. 2003;7:572\u20139.","journal-title":"Mol Ther"},{"key":"1455_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00401-019-01973-6","volume":"137","author":"M Masnata","year":"2019","unstructured":"Masnata M, Sciacca G, Maxan A, Bousset L, Denis HL, Lauruol F, et al. Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019;137:981\u20131001.","journal-title":"Acta Neuropathol"},{"key":"1455_CR52","doi-asserted-by":"publisher","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","volume":"7","author":"LB Menalled","year":"2012","unstructured":"Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175. PLoS One. 2012;7:e49838.","journal-title":"PLoS One"},{"key":"1455_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetheringto C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493\u2013506.","journal-title":"Cell"},{"key":"1455_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104569","volume":"132","author":"HL Denis","year":"2019","unstructured":"Denis HL, David LS, Cicchetti F. Antibody-based therapies for Huntington\u2019s disease: current status and future directions. Neurobiol Dis. 2019;132:104569.","journal-title":"Neurobiol Dis"},{"key":"1455_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/srep31652","volume":"6","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016;6:31652.","journal-title":"Sci Rep"},{"key":"1455_CR56","doi-asserted-by":"publisher","first-page":"A92","DOI":"10.1136\/jnnp-2016-314597.262","volume":"87","author":"G Ellrichmann","year":"2016","unstructured":"Ellrichmann G, Blusch A, Fatoba O, Brunner J, Pitarokoili K, Hayardeny L, et al. L7 Laquinimod in the R6\/2 mouse model of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2016;87:A92.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1455_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04990-1","volume":"7","author":"G Ellrichmann","year":"2017","unstructured":"Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayarden L, et al. Laquinimod treatment in the R6\/2 mouse model. Sci Rep. 2017;7:4947.","journal-title":"Sci Rep"},{"key":"1455_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2004.02.016","volume":"156","author":"JS Yang","year":"2004","unstructured":"Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1\/Th2 balance and induces the Th3 cytokine TGF-\u03b2 in Lewis rats. J Neuroimmunol. 2004;156:3\u20139.","journal-title":"J Neuroimmunol"},{"key":"1455_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad084","volume":"5","author":"AA Roussakis","year":"2023","unstructured":"Roussakis AA, Gennaro M, Gordon MF, Reilmann R, Borowsky B, Rynkowski G, et al. A PET-CT study on neuroinflammation in Huntington\u2019s disease patients participating in a randomized trial with laquinimod. Brain Commun. 2023;5:fcad084.","journal-title":"Brain Commun"},{"key":"1455_CR60","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.S16.007","volume":"92","author":"R Reilmann","year":"2019","unstructured":"Reilmann R, Gordon MF, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, et al. The efficacy and safety results of laquinimod as a treatment for Huntington disease (LEGATO-HD) (S16. 007). Neurology. 2019;92:S16.007.","journal-title":"Neurology"},{"key":"1455_CR61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","volume":"135","author":"I St-Amour","year":"2018","unstructured":"St-Amour I, Turgeon A, Goupil C, Planel E, H\u00e9bert SS. Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease. Acta Neuropathol. 2018;135:249\u201365.","journal-title":"Acta Neuropathol"},{"key":"1455_CR62","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","volume":"69","author":"A Snyder-Keller","year":"2010","unstructured":"Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice. J Neuropathol Exp Neurol. 2010;69:1078\u201385.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1455_CR63","doi-asserted-by":"publisher","first-page":"11563","DOI":"10.1073\/pnas.0505321102","volume":"102","author":"WJ Wolfgang","year":"2005","unstructured":"Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, et al. Suppression of Huntington\u2019s disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA. 2005;102:11563\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR64","doi-asserted-by":"publisher","first-page":"e29199","DOI":"10.1371\/journal.pone.0029199","volume":"6","author":"DC Butler","year":"2011","unstructured":"Butler DC, Messer A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One. 2011;6:e29199.","journal-title":"PLoS One"},{"key":"1455_CR65","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1073\/pnas.022631799","volume":"99","author":"A Khoshnan","year":"2002","unstructured":"Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA. 2002;99:1002\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR66","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","volume":"28","author":"AL Southwell","year":"2008","unstructured":"Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci. 2008;28:9013\u201320.","journal-title":"J Neurosci"},{"key":"1455_CR67","first-page":"7120753","volume":"2016","author":"IA Amaro","year":"2016","unstructured":"Amaro IA, Henderson LA. An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal Huntingtin fragment (s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model. J Neurodegener Dis. 2016;2016:7120753.","journal-title":"J Neurodegener Dis"},{"key":"1455_CR68","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/brain\/awad280","volume":"147","author":"ST Brady","year":"2024","unstructured":"Brady ST, Mesnard-Hoaglin NA, Mays S, Priego M, Dziechciowska J, Morris S, et al. Toxic effects of mutant huntingtin in axons are mediated by its proline-rich domain. Brain. 2024;147:2098\u2013113.","journal-title":"Brain"},{"key":"1455_CR69","doi-asserted-by":"publisher","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","volume":"29","author":"AL Southwell","year":"2009","unstructured":"Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease. J Neurosci. 2009;29:13589\u2013602.","journal-title":"J Neurosci"},{"key":"1455_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104943","volume":"141","author":"S Bartl","year":"2020","unstructured":"Bartl S, Oueslati A, Southwell AL, Siddu A, Parth M, David LS, et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: implications for the treatment of Huntington\u2019s disease. Neurobiol Dis. 2020;141:104943.","journal-title":"Neurobiol Dis"},{"key":"1455_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106376","volume":"190","author":"S Bartl","year":"2024","unstructured":"Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, et al. Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. Neurobiol Dis. 2024;190:106376.","journal-title":"Neurobiol Dis"},{"key":"1455_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brainres.2018.11.034","volume":"1707","author":"XG Liu","year":"2019","unstructured":"Liu XG, Lu S, Liu DQ, Zhang L, Zhang LX, Yu XL, et al. ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson\u2019s and Huntington\u2019s diseases. Brain Res. 2019;1707:141\u201353.","journal-title":"Brain Res"},{"key":"1455_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/srep36631","volume":"6","author":"J Zha","year":"2016","unstructured":"Zha J, Liu XM, Zhu J, Liu SY, Lu S, Xu PX, et al. A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Sci Rep. 2016;6:36631.","journal-title":"Sci Rep"},{"key":"1455_CR74","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/protein\/gzl036","volume":"199","author":"H Barkhordarian","year":"2006","unstructured":"Barkhordarian H, Emadi S, Schulz P, Sierks MR. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel. 2006;199:497\u2013502.","journal-title":"Protein Eng Des Sel"},{"key":"1455_CR75","doi-asserted-by":"publisher","first-page":"e5727","DOI":"10.1371\/journal.pone.0005727","volume":"4","author":"E Kvam","year":"2009","unstructured":"Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One. 2009;4:e5727.","journal-title":"PLoS One"},{"key":"1455_CR76","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4049\/jimmunol.0903302","volume":"184","author":"T Okuno","year":"2010","unstructured":"Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, et al. Roles of Sema4D\u2013plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:1499\u2013506.","journal-title":"J Immunol"},{"key":"1455_CR77","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/19420862.2015.1102813","volume":"8","author":"TL Fisher","year":"2016","unstructured":"Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, et al. Generation and preclinical characterization of an antibody specific for SEMA4D. MAbs. 2016;8:150\u201362.","journal-title":"MAbs"},{"key":"1455_CR78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","volume":"76","author":"AL Southwell","year":"2015","unstructured":"Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2015;76:46\u201356.","journal-title":"Neurobiol Dis"},{"key":"1455_CR79","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/563784","volume":"2011","author":"A Nayak","year":"2011","unstructured":"Nayak A, Ansar R, Verma SK, Bonifati DM, Kishore U. Huntington\u2019s disease: an immune perspective. Neurol Res Int. 2011;2011:563784.","journal-title":"Neurol Res Int"},{"key":"1455_CR80","doi-asserted-by":"publisher","first-page":"652","DOI":"10.14336\/AD.2019.0118","volume":"10","author":"K Cho","year":"2019","unstructured":"Cho K. Emerging roles of complement protein C1q in neurodegeneration. Aging Dis. 2019;10:652\u201363.","journal-title":"Aging Dis"},{"key":"1455_CR81","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2023.02.075","volume":"655","author":"D Kumar","year":"2023","unstructured":"Kumar D, Hasan GM, Islam A, Hassan MI. Therapeutic targeting of Huntington\u2019s disease: molecular and clinical approaches. Biochem Biophys Res Commun. 2023;655:18\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"1455_CR82","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1091581817740873","volume":"36","author":"JA Lansita","year":"2017","unstructured":"Lansita JA, Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S. Nonclinical development of ANX005: A humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36:449\u201362.","journal-title":"Int J Toxicol"},{"key":"1455_CR83","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","volume":"28","author":"A Feigin","year":"2022","unstructured":"Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, et al. Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28:2183\u201393.","journal-title":"Nat Med"},{"key":"1455_CR84","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/13543784.2024.2348738","volume":"33","author":"SE Field","year":"2024","unstructured":"Field SE, Curle AJ, Barker RA. Inflammation and Huntington\u2019s disease: a neglected therapeutic target? Expert Opin Investig Drugs. 2024;33:451\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"1455_CR85","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","volume":"95","author":"SB Prusiner","year":"1998","unstructured":"Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR86","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1126\/science.6801762","volume":"216","author":"SB Prusiner","year":"1982","unstructured":"Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136\u201344.","journal-title":"Science"},{"key":"1455_CR87","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114714","volume":"13","author":"AK Lakkaraju","year":"2021","unstructured":"Lakkaraju AK, Frontzek K, Lemes E, Herrmann U, Losa M, Marpakwar R, et al. Loss of PIKfyve drives the spongiform degeneration in prion diseases. EMBO Mol Med. 2021;13:e14714.","journal-title":"EMBO Mol Med"},{"key":"1455_CR88","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0092-8674(00)81163-0","volume":"93","author":"SB Prusiner","year":"1998","unstructured":"Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell. 1998;93:337\u201348.","journal-title":"Cell"},{"key":"1455_CR89","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00401-015-1508-y","volume":"131","author":"C McKinnon","year":"2016","unstructured":"McKinnon C, Goold R, Andre R, Devoy A, Ortega Z, Moonga J, et al. Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin\u2013proteasome system. Acta Neuropathol. 2016;131:411\u201325.","journal-title":"Acta Neuropathol"},{"key":"1455_CR90","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.4161\/auto.21482","volume":"8","author":"Y Xu","year":"2012","unstructured":"Xu Y, Tian C, Wang SB, Xie WL, Guo Y, Zhang J, et al. Activation of the macroautophagic system in scrapie-infected experimental animals and human genetic prion diseases. Autophagy. 2012;8:1604\u201320.","journal-title":"Autophagy"},{"key":"1455_CR91","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1146\/annurev-pathmechdis-012418-013109","volume":"14","author":"CJ Sigurdson","year":"2019","unstructured":"Sigurdson CJ, Bartz JC, Glatzel M. Cellular and molecular mechanisms of prion disease. Annu Rev Pathol. 2019;14:497\u2013516.","journal-title":"Annu Rev Pathol"},{"key":"1455_CR92","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/brain\/awh249","volume":"127","author":"M Pocchiari","year":"2004","unstructured":"Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, et al. Predictors of survival in sporadic Creutzfeldt\u2013Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127:2348\u201359.","journal-title":"Brain"},{"key":"1455_CR93","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1532-5415.1973.tb01676.x","volume":"21","author":"Y Herishanu","year":"1973","unstructured":"Herishanu Y. Antiviral drugs in Jakob\u2010Creutzfeldt disease. J Am Geriatr Soc. 1973;21:229\u201331.","journal-title":"J Am Geriatr Soc"},{"key":"1455_CR94","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0140-6736(84)92880-0","volume":"1","author":"A David","year":"1984","unstructured":"David A, Grant R, Ballantyne J. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet. 1984;1:512\u20133.","journal-title":"Lancet"},{"key":"1455_CR95","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1006\/exnr.1997.6559","volume":"147","author":"S Perovic","year":"1997","unstructured":"Perovic S, Schr\u00f6der HC, Pergande G, Ushijima H, M\u00fcller WE. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol. 1997;147:518\u201324.","journal-title":"Exp Neurol"},{"key":"1455_CR96","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","volume":"62","author":"M Otto","year":"2004","unstructured":"Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004;62:714\u20138.","journal-title":"Neurology"},{"key":"1455_CR97","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","volume":"81","author":"MD Geschwind","year":"2013","unstructured":"Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81:2015\u201323.","journal-title":"Neurology"},{"key":"1455_CR98","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:150\u20138.","journal-title":"Lancet Neurol"},{"key":"1455_CR99","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00441-023-03749-7","volume":"392","author":"S Napper","year":"2023","unstructured":"Napper S, Schatzl HM. Vaccines for prion diseases: a realistic goal? Cell Tissue Res. 2023;392:367\u201392.","journal-title":"Cell Tissue Res"},{"key":"1455_CR100","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/pathogens9030216","volume":"9","author":"Y Ma","year":"2020","unstructured":"Ma Y, Ma J. Immunotherapy against prion disease. Pathogens. 2020;9:216.","journal-title":"Pathogens"},{"key":"1455_CR101","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.4049\/jimmunol.0804385","volume":"183","author":"P Gourdain","year":"2009","unstructured":"Gourdain P, Gregoire S, Iken S, Bachy V, Dorban G, Chaigneau T, et al. Adoptive transfer of T lymphocytes sensitized against the prion protein attenuates prion invasion in scrapie-infected mice. J Immunol. 2009;183:6619\u201328.","journal-title":"J Immunol"},{"key":"1455_CR102","first-page":"e1002216","volume":"7","author":"S Iken","year":"2011","unstructured":"Iken S, Bachy V, Gourdain P, Lim A, Gr\u00e9goire S, Chaigneau T, et al. Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. PLoSPathog. 2011;7:e1002216.","journal-title":"PLoSPathog"},{"key":"1455_CR103","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1099\/vir.0.013417-0","volume":"91","author":"V Bachy","year":"2010","unstructured":"Bachy V, Ballerini C, Gourdain P, Prignon A, Iken S, Antoine N, et al. Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie. J Gen Virol. 2010;91:809\u201320.","journal-title":"J Gen Virol"},{"key":"1455_CR104","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/19336896.2015.1071761","volume":"9","author":"R Taschuk","year":"2015","unstructured":"Taschuk R, Van der Merwe J, Marciniuk K, Potter A, Cashman N, Griebel P, et al. In vitro neutralization of prions with PrPSc-specific antibodies. Prion. 2015;9:292\u2013303.","journal-title":"Prion"},{"key":"1455_CR105","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/1521-4141(200108)31:8<2338::AID-IMMU2338>3.0.CO;2-V","volume":"31","author":"L Souan","year":"2001","unstructured":"Souan L, Tal Y, Felling Y, Cohen IR, Taraboulos A, Mor F. Modulation of proteinase\u2010K resistant prion protein by prion peptide immunization. Eur J Immunol. 2001;31:2338\u201346.","journal-title":"Eur J Immunol"},{"key":"1455_CR106","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0165-5728(02)00316-8","volume":"132","author":"MF Koller","year":"2002","unstructured":"Koller MF, Grau T, Christen P. Induction of antibodies against murine full-length prion protein in wild-type mice. J Neuroimmunol. 2002;132:113\u20136.","journal-title":"J Neuroimmunol"},{"key":"1455_CR107","doi-asserted-by":"publisher","first-page":"18524","DOI":"10.1074\/jbc.M210723200","volume":"278","author":"S Gilch","year":"2003","unstructured":"Gilch S, Wopfner F, Renner-Muller I, Kremmer E, Bauer C, Wolf E, et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem. 2003;278:18524\u201331.","journal-title":"J Biol Chem"},{"key":"1455_CR108","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.neuroscience.2005.02.031","volume":"133","author":"F Goni","year":"2005","unstructured":"Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience. 2005;133:413\u201321.","journal-title":"Neuroscience"},{"key":"1455_CR109","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.1016\/j.vaccine.2011.10.017","volume":"29","author":"D Ishibashi","year":"2011","unstructured":"Ishibashi D, Yamanaka H, Mori T, Yamaguchi N, Yamaguchi Y, Nishida N, et al. Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylargininedihydrolase in mice. Vaccine. 2011;29:9321\u20138.","journal-title":"Vaccine"},{"key":"1455_CR110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0002-9440(10)64151-X","volume":"161","author":"EM Sigurdsson","year":"2002","unstructured":"Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, et al. Immunization delays the onset of prion disease in mice. Am J Pathol. 2002;161:13\u20137.","journal-title":"Am J Pathol"},{"key":"1455_CR111","doi-asserted-by":"publisher","first-page":"10629","DOI":"10.3390\/ijms231810629","volume":"23","author":"G Triller","year":"2022","unstructured":"Triller G, Garyfallos DA, Papavasiliou FN, Sklaviadis T, Stavropoulos P, Xanthopoulos K. Immunization with genetically modified trypanosomes provides protection against transmissible spongiform encephalopathies. Int J Mol Sci. 2022;23:10629.","journal-title":"Int J Mol Sci"},{"key":"1455_CR112","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/v13050811","volume":"13","author":"M Eiden","year":"2021","unstructured":"Eiden M, Gedvilait A, Leidel F, Ulrich RG, Groschup MH. Vaccination with prion peptide-displaying polyomavirus-like particles prolongs incubation time in scrapie-infected mice. Viruses. 2021;13:811.","journal-title":"Viruses"},{"key":"1455_CR113","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/19336896.2022.2153551","volume":"16","author":"KH Shim","year":"2022","unstructured":"Shim KH, Sharma N, An SSA. Prion therapeutics: lessons from the past. Prion. 2022;16:265\u201394.","journal-title":"Prion"},{"key":"1455_CR114","doi-asserted-by":"publisher","first-page":"e3872","DOI":"10.1371\/journal.pone.0003872","volume":"3","author":"M Polymenidou","year":"2008","unstructured":"Polymenidou M, Moos R, Scott M, Sigurdson C, Shi Y, Yajima B, et al. The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One. 2008;3:e3872.","journal-title":"PLoS One"},{"key":"1455_CR115","first-page":"e1007335","volume":"14","author":"M Bardelli","year":"2018","unstructured":"Bardelli M, Frontzek K, Simonelli L, Hornemann S, Pedotti M, Mazzola F, et al. A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity. PLoSPathog. 2018;14:e1007335.","journal-title":"PLoSPathog"},{"key":"1455_CR116","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bsheal.2020.09.001","volume":"3","author":"C Chen","year":"2021","unstructured":"Chen C, Dong X. Therapeutic implications of prion diseases. Biosaf Health. 2021;3:92\u2013100.","journal-title":"Biosaf Health"},{"key":"1455_CR117","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/35094590","volume":"2","author":"A Aguzzi","year":"2001","unstructured":"Aguzzi A, Glatzel M, Montrasio F, Prinz M, Heppner FL. Interventional strategies against prion diseases. Nat Rev Neurosci. 2001;2:745\u20139.","journal-title":"Nat Rev Neurosci"},{"key":"1455_CR118","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.nbd.2009.01.013","volume":"34","author":"MJ Sadowski","year":"2009","unstructured":"Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, Kascsak RB, et al. Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1\/22L and in the lymphoreticular system in vivo. Neurobiol Dis. 2009;34:267\u201378.","journal-title":"Neurobiol Dis"},{"key":"1455_CR119","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/1348-0421.12037","volume":"57","author":"N Ohsawa","year":"2013","unstructured":"Ohsawa N, Song CH, Suzuki A, Furuoka H, Hasebe R, Horiuchi M. Therapeutic effect of peripheral administration of an anti\u2010prion protein antibody on mice infected with prions. Microbiol Immunol. 2013;57:288\u201397.","journal-title":"Microbiol Immunol"},{"key":"1455_CR120","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/362543a0","volume":"362","author":"G Forloni","year":"1993","unstructured":"Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, et al. Neurotoxicity of a prion protein fragment. Nature. 1993;362:543\u20136.","journal-title":"Nature"},{"key":"1455_CR121","doi-asserted-by":"publisher","first-page":"27236","DOI":"10.1074\/jbc.M413441200","volume":"280","author":"EM Norstrom","year":"2005","unstructured":"Norstrom EM, Mastrianni JA. The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation. J Biol Chem. 2005;280:27236\u2013243.","journal-title":"J Biol Chem"},{"key":"1455_CR122","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1096\/fj.11-200923","volume":"2","author":"C Bett","year":"2012","unstructured":"Bett C, Fern\u00e1ndez-Borges N, Kurt TD, Lucero M, Nilsson KPR, Castilla J, et al. Structure of the \u03b22-\u03b12 loop and interspecies prion transmission. FASEB J. 2012;2:2868\u201376.","journal-title":"FASEB J"},{"key":"1455_CR123","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1073\/pnas.1712155114","volume":"114","author":"E Caldarulo","year":"2017","unstructured":"Caldarulo E, Barducci A, W\u00fcthrich K, Parrinello M. Prion protein \u03b22\u2013\u03b12 loop conformational landscape. Proc Natl Acad Sci USA. 2017;114:9617\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR124","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1523\/JNEUROSCI.4636-13.2014","volume":"3","author":"TD Kurt","year":"2014","unstructured":"Kurt TD, Bett C, Fern\u00e1ndez-Borges N, Joshi-Barr S, Hornemann S, R\u00fclicke T, et al. Prion transmission prevented by modifying the \u03b22-\u03b12 loop structure of host PrPC. J Neurosci. 2014;3:1022\u20137.","journal-title":"J Neurosci"},{"key":"1455_CR125","first-page":"e1008139","volume":"15","author":"R Abskharon","year":"2019","unstructured":"Abskharon R, Wang F, Wohlkonig A, Ruan J, Soror S, Giachin G, et al. Structural evidence for the critical role of the prion protein hydrophobic region in forming an infectious prion. PLoSPathog. 2019;15:e1008139.","journal-title":"PLoSPathog"},{"key":"1455_CR126","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/acs.jcim.2c01062","volume":"63","author":"L Mollica","year":"2022","unstructured":"Mollica L, Giachin G. Recognition mechanisms between a nanobody and disordered epitopes of the human prion protein: an integrative molecular dynamics study. J Chem Info Model. 2022;63:531\u201345.","journal-title":"J Chem Info Model"},{"key":"1455_CR127","doi-asserted-by":"publisher","first-page":"e2028","DOI":"10.1212\/WNL.0000000000009183","volume":"95","author":"K Frontzek","year":"2020","unstructured":"Frontzek K, Carta M, Losa M, Epskamp M, Meisl G, Anane A, et al. Autoantibodies against the prion protein in individuals with PRNP mutations. Neurology. 2020;95:e2028\u201337.","journal-title":"Neurology"},{"key":"1455_CR128","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S1474-4422(22)00082-5","volume":"21","author":"S Mead","year":"2022","unstructured":"Mead S, Khalili-Shirazi A, Potter C, Mok T, Nihat A, Hyare H, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt\u2013Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol. 2022;21:342\u201354.","journal-title":"Lancet Neurol"},{"key":"1455_CR129","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/1573395054065179","volume":"1","author":"DH Cribbs","year":"2005","unstructured":"Cribbs DH, Agadjanyan MG. Immunotherapy for Alzheimer\u2019s disease: potential problems and possible solutions. Curr Immunol Rev. 2005;1:139\u201355.","journal-title":"Curr Immunol Rev"},{"key":"1455_CR130","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1099\/vir.0.83578-0","volume":"89","author":"CH Song","year":"2008","unstructured":"Song CH, Furuoka H, Kim CL, Ogino M, Suzuki A, Hasebe R, et al. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol. 2008;89:1533\u201344.","journal-title":"J Gen Virol"},{"key":"1455_CR131","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1093\/emboj\/20.21.5863","volume":"20","author":"S Gauczynski","year":"2001","unstructured":"Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, et al. The 37-kDa\/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J. 2001;20:5863\u201375.","journal-title":"EMBO J"},{"key":"1455_CR132","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/505914","volume":"194","author":"S Gauczynski","year":"2006","unstructured":"Gauczynski S, Nikles D, El-Gogo S, Papy-Garcia D, Rey C, Alban S, et al. The 37-kDa\/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfatedglycanes. J Infect Dis. 2006;194:702\u20139.","journal-title":"J Infect Dis"},{"key":"1455_CR133","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.molimm.2007.04.030","volume":"45","author":"C Zuber","year":"2008","unstructured":"Zuber C, Knackmuss S, Rey C, Reusch U, R\u00f6ttgen P, Fr\u00f6hlich T, et al. Single chain Fv antibodies directed against the 37 kDa\/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol. 2008;45:144\u201351.","journal-title":"Mol Immunol"},{"key":"1455_CR134","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1099\/vir.0.83670-0","volume":"89","author":"C Zuber","year":"2008","unstructured":"Zuber C, Mitteregger G, Schuhmann N, Rey C, Knackmuss S, Rupprecht W, et al. Delivery of single-chain antibodies (scFvs) directed against the 37\/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol. 2008;89:2055\u201361.","journal-title":"J Gen Virol"},{"key":"1455_CR135","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1126\/science.275.5298.402","volume":"275","author":"CI Lasmezas","year":"1997","unstructured":"Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science. 1997;275:402\u20135.","journal-title":"Science"},{"key":"1455_CR136","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1093\/emboj\/18.23.6855","volume":"8","author":"JC Manson","year":"1999","unstructured":"Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, et al. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 1999;8:6855\u201364.","journal-title":"EMBO J"},{"key":"1455_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1164779","volume":"10","author":"N Jaffr\u00e9","year":"2023","unstructured":"Jaffr\u00e9 N, Delmotte J, Mikol J, Deslys JP, Comoy E. Unexpected decrease of full-length prion protein in macaques inoculated with prion-contaminated blood products. Front Mol Biosci. 2023;10:1164779.","journal-title":"Front Mol Biosci"},{"key":"1455_CR138","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1063005","volume":"293","author":"RM Zinkernagel","year":"2001","unstructured":"Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science. 2001;293:251\u20133.","journal-title":"Science"},{"key":"1455_CR139","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.coi.2004.07.008","volume":"16","author":"FL Heppner","year":"2004","unstructured":"Heppner FL, Aguzzi A. Recent developments in prion immunotherapy. Curr opin Immunol. 2004;16:594\u20138.","journal-title":"Curr opin Immunol"},{"key":"1455_CR140","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1189\/jlb.1106665","volume":"81","author":"DS Spinner","year":"2007","unstructured":"Spinner DS, Kascsak RB, LaFauci G, Meeker HC, Ye X, Flory MJ, et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein [PrPSc] in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol. 2007;81:1374\u201385.","journal-title":"J Leukoc Biol"},{"key":"1455_CR141","first-page":"57","volume":"5","author":"JT Burchell","year":"2016","unstructured":"Burchell JT, Panegyres PK. Prion diseases: immunotargets and therapy. Immunotargets Ther. 2016;5:57\u201368.","journal-title":"Immunotargets Ther"},{"key":"1455_CR142","volume":"2013","author":"K Marciniuk","year":"2013","unstructured":"Marciniuk K, Taschuk R, Napper S. Evidence for prion\u2010like mechanisms in several neurodegenerative diseases: Potential implications for immunotherapy. J Immunol Res. 2013;2013:473706.","journal-title":"J Immunol Res"},{"key":"1455_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.654739","volume":"12","author":"I Mortada","year":"2021","unstructured":"Mortada I, Farah R, Nabha S, Ojcius DM, Fares Y, Almawi WY, et al. Immunotherapies for neurodegenerative diseases. Front Neurol. 2021;12:654739.","journal-title":"Front Neurol"},{"key":"1455_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202300114","volume":"24","author":"M Bonsor","year":"2024","unstructured":"Bonsor M, Ammar O, Schnoegl S, Wanker EE, Silva Ramos E. Polyglutamine disease proteins: commonalities and differences in interaction profiles and pathological effects. Proteomics. 2024;24:e2300114.","journal-title":"Proteomics"},{"key":"1455_CR145","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.07558","volume":"4","author":"CA Lasagna-Reeves","year":"2015","unstructured":"Lasagna-Reeves CA, Rousseaux MW, Guerrero-Mu\u00f1oz MJ, Park J, Jafar-Nejad P, Richman R, et al. A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. Elife. 2015;4:e07558.","journal-title":"Elife"},{"key":"1455_CR146","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.10891","volume":"4","author":"CA Lasagna-Reeves","year":"2015","unstructured":"Lasagna-Reeves CA, Rousseaux M, Guerrero-Munoz MJ, Vilanova-Velez L, Park J, See L, et al. Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows spinocerebellar ataxia type 1 phenotypes. Elife. 2015;4:e10891.","journal-title":"Elife"},{"key":"1455_CR147","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s13167-024-00368-2","volume":"15","author":"T Raschka","year":"2024","unstructured":"Raschka T, Li Z, Ga\u00dfner H, Kohl Z, Jukic J, Marxreiter F, et al. Unraveling progression subtypes in people with Huntington\u2019s disease. EPMA J. 2024;15:275\u201387.","journal-title":"EPMA J"},{"key":"1455_CR148","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/cells13100829","volume":"13","author":"J Ryu","year":"2024","unstructured":"Ryu J, Statz JP, Chan W, Oyama K, Custer M, Wienisch M, et al. Generation of rhesus macaque embryos with expanded CG trinucleotide repeats in the huntingtin gene. Cells. 2024;13:829.","journal-title":"Cells"},{"key":"1455_CR149","doi-asserted-by":"publisher","first-page":"9295","DOI":"10.1073\/pnas.151242598","volume":"98","author":"M Enari","year":"2001","unstructured":"Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA. 2001;98:9295\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR150","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/35089090","volume":"412","author":"D Peretz","year":"2001","unstructured":"Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 2001;412:739\u201343.","journal-title":"Nature"},{"key":"1455_CR151","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1871527321666211228100955","volume":"22","author":"AC Mondal","year":"2023","unstructured":"Mondal AC. Immunotherapeutic approaches for the treatment of neurodegenerative diseases: challenges and outcomes. CNS NeurolDisord Drug Targets. 2023;22:404\u201316.","journal-title":"CNS NeurolDisord Drug Targets"},{"key":"1455_CR152","unstructured":"Wave Life Sciences reports third quarter financial results and provides business update [press release]. Cambridge, Massachusetts: Wave Life Sciences; November 09, 2020."},{"key":"1455_CR153","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1212\/WNL.94.15_supplement.4703","volume":"94","author":"E Dale","year":"2020","unstructured":"Dale E, Frank-Kamenetsky M, Taborn K, Aklilu K, Liu Y, Berkovitch S, et al. Stereopure oligonucleotides for the selective silencing of mutant Huntingtin. Neurology. 2020;94:4703.","journal-title":"Neurology"},{"key":"1455_CR154","doi-asserted-by":"publisher","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","volume":"6","author":"MM Evers","year":"2011","unstructured":"Evers MM, Pepers BA, van Deutekom JC, Mulders SA, den Dunnen JT, Aartsma-Rus A, et al. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One. 2011;6:e24308.","journal-title":"PLoS One"},{"key":"1455_CR155","doi-asserted-by":"publisher","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","volume":"12","author":"NA Datson","year":"2017","unstructured":"Datson NA, Gonz\u00e1lez-Barriga A, Kourkouta E, Weij R, van de Giessen J, Mulders S, et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One. 2017;12:e0171127.","journal-title":"PLoS One"},{"key":"1455_CR156","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","volume":"2","author":"JY Li","year":"2005","unstructured":"Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx. 2005;2:447\u201364.","journal-title":"NeuroRx"},{"key":"1455_CR157","unstructured":"Triplet Therapeutics presents preclinical data for TTX-3360, announces equity pledge at the CHDI Foundation\u2019s 16th Annual HD Therapeutics Conference [press release]; April 27, 2021."},{"key":"1455_CR158","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/ijms21062146","volume":"21","author":"F Marxreiter","year":"2020","unstructured":"Marxreiter F, Stemick J, Kohl Z. Huntingtin lowering strategies. Int J Mol Sci. 2020;21:2146.","journal-title":"Int J Mol Sci"},{"key":"1455_CR159","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031\u201344.","journal-title":"Neuron"},{"key":"1455_CR160","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum Gene Ther. 2014;25:461\u201374.","journal-title":"Hum Gene Ther"},{"key":"1455_CR161","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.brainres.2014.06.011","volume":"1581","author":"M Ghilan","year":"2014","unstructured":"Ghilan M, Bostrom CA, Hryciw BN, Simpson JM, Christie BR, Gil-Mohapel J. YAC128 Huntington\u05f3 s disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease. Brain Res. 2014;1581:117\u201328.","journal-title":"Brain Res"},{"key":"1455_CR162","unstructured":"Voyager therapeutics announces preclinical data for Huntington\u2019s Disease and Amyotrophic lateral sclerosis programs at the Congress Of The European Society Of Gene and Cell Therapy [press release]; Cambridge, Massachusetts, October 16, 2018."},{"key":"1455_CR163","unstructured":"Voyager therapeutics provides regulatory update On VY-HTT01 Program [press release]; Cambridge, Massachusetts, October 13, 2020."},{"key":"1455_CR164","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 2017;16:837\u201347.","journal-title":"Lancet Neurol"},{"key":"1455_CR165","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci USA. 2005;102:5820\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR166","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/mt.2008.50","volume":"16","author":"NR Franich","year":"2008","unstructured":"Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. AAV vector\u2013mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease. Mol Ther. 2008;16:947\u201356.","journal-title":"Mol Ther"},{"key":"1455_CR167","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol Ther. 2011;19:2152\u201362.","journal-title":"Mol Ther"},{"key":"1455_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.7","volume":"5","author":"J Miniarikova","year":"2016","unstructured":"Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, et al. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease. Mol Ther Nucleic Acids. 2016;5:e297.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1455_CR169","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gt.2017.71","volume":"24","author":"J Miniarikova","year":"2017","unstructured":"Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease. Gene Ther. 2017;24:630\u20139.","journal-title":"Gene Ther"},{"key":"1455_CR170","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","volume":"15","author":"S Keskin","year":"2019","unstructured":"Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, Vall\u00e8s A, et al. AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes. Mol Ther Methods Clin Dev. 2019;15:275\u201384.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1455_CR171","first-page":"1115","volume":"26","author":"AL Southwell","year":"2017","unstructured":"Southwell AL, Skotte NH, Villanueva EB, \u00d8stergaard ME, Gu X, Kordasiewicz HB, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Hum Mol Genet. 2017;26:1115\u201332.","journal-title":"Hum Mol Genet"},{"key":"1455_CR172","first-page":"36","volume":"48","author":"NS Caron","year":"2020","unstructured":"Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, et al. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020;48:36\u201354.","journal-title":"Nucleic Acids Res"},{"key":"1455_CR173","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","volume":"13","author":"EA Spronck","year":"2019","unstructured":"Spronck EA, Brouwers CC, Vall\u00e8s A, de Haan M, Petry H, van Deventer SJ, et al. AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models. Mol Ther Methods Clin Dev. 2019;13:334\u201343.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1455_CR174","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers MM, Miniarikova J, Juhas S, Vall\u00e8s A, Bohuslavova B, Juhasova J, et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model. Mol Ther. 2018;26:2163\u201377.","journal-title":"Mol Ther"},{"key":"1455_CR175","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JHD-200002","volume":"9","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues FB, Wild EJ. Huntington\u2019s disease clinical trials corner: April 2020. J Huntington\u2019s Dis. 2020;9:185\u201397.","journal-title":"J Huntington\u2019s Dis"},{"key":"1455_CR176","unstructured":"UniQure. Safety and proof-of-concept (POC) study with AMT-130 in adults with early manifest Huntington Disease; 2019 (https:\/\/ClinicalTrials.gov\/show\/NCT04120493)."},{"key":"1455_CR177","unstructured":"UniQure announces completion of enrollment in first cohort of Phase I\/II clinical trial of AMT-130 for the treatment of Huntington\u2019s disease; 2021 (https:\/\/www.biospace.com\/article\/releases\/uniqure-announces-clinical-update-on-first-patients-in-phase-i-ii-clinical-trial-of-amt-130-gene-therapy-for-the-treatment-of-huntington-s-disease\/)."},{"key":"1455_CR178","unstructured":"UniQure announces positive recommendation from data safety monitoring board of Phase I\/II clinical trial of AMT-130 for the treatment of Huntington\u2019s Disease [press release]; Lexington, Massachusetts; Amsterdam, The Netherlands: UniQure, February 8, 2021."},{"key":"1455_CR179","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40265-018-0868-8","volume":"78","author":"HK Shorrock","year":"2018","unstructured":"Shorrock HK, Gillingwater TH, Groen EJ. Overview of current drugs and molecules in development for spinal muscular atrophy therapy. Drugs. 2018;78:293\u20135.","journal-title":"Drugs"},{"key":"1455_CR180","unstructured":"Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington\u2019s disease (HD) [press release]; Basel, Switzerland, October 21, 2020."},{"key":"1455_CR181","unstructured":"Bhattacharyya A. Identification and development of orally administered, CNS-penetrant small molecules that lower huntingtin protein levels by inducing a novel splicing event that alters the stability of huntingtin mRNA. CHDI HD Therapeutics Conference. Palm Springs, California; 2019."},{"key":"1455_CR182","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28:6182\u201395.","journal-title":"J Neurosci"},{"key":"1455_CR183","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3390\/jcm9113682","volume":"9","author":"MJ Brownstein","year":"2020","unstructured":"Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, et al. Safety and tolerability of srx246, a vasopressin 1a antagonist, in irritable Huntington\u2019s disease patients\u2014a randomized phase 2 clinical trial. J Clin Med. 2020;9:3682.","journal-title":"J Clin Med"},{"key":"1455_CR184","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.2147\/NDT.S111083","volume":"12","author":"AL McGregor","year":"2016","unstructured":"McGregor AL, Dysart J, Tingle MD, Russell BR, Kydd RR, Finucane G. Varenicline improves motor and cognitive symptoms in early Huntington\u2019s disease. Neuropsychiatr Dis Treat. 2016;12:2381\u20136.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1455_CR185","unstructured":"Sage Therapeutics announces planned progression of SAGE-718 to Phase 2 in Huntington\u2019s disease and presentations at the 2019 annual meeting of the American College of Neuropsychopharmacology (ACNP) [press release]; December 10, 2019 (https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-planned-progression-sage-718-phase-2)."},{"key":"1455_CR186","unstructured":"Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth [press release]; May 13, 2021 (https:\/\/www.biospace.com\/article\/releases\/sage-therapeutics-to-host-sage-science-spotlight-sage-718-in-depth\/)."},{"key":"1455_CR187","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"B Zeitler","year":"2019","unstructured":"Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease. Nat Med. 2019;25:1131\u201342.","journal-title":"Nat Med"},{"key":"1455_CR188","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1602\/neurorx.2.3.465","volume":"2","author":"LB Menalled","year":"2005","unstructured":"Menalled LB. Knock-in mouse models of Huntington\u2019s disease. NeuroRx. 2005;2:465\u201370.","journal-title":"NeuroRx"},{"key":"1455_CR189","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-016-0128-x","volume":"11","author":"C Agust\u00edn-Pav\u00f3n","year":"2016","unstructured":"Agust\u00edn-Pav\u00f3n C, Mielcarek M, Garriga-Canut M, Isalan M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener. 2016;11:64.","journal-title":"Mol Neurodegener"},{"key":"1455_CR190","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/jnnp.73.6.678","volume":"73","author":"AE Rosser","year":"2002","unstructured":"Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington\u2019s disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry. 2002;73:678\u201385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1455_CR191","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, et al. NEST-UK collaboration. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84:657\u201365.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1455_CR192","unstructured":"Azidus Brasil. Clinical extension study for safety and efficacy evaluation of cellavita-HD administration in Huntington\u2019s patients. (ADORE-EXT); 2020 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219241)."},{"key":"1455_CR193","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1128\/JVI.02145-09","volume":"84","author":"S Ghaemmaghami","year":"2010","unstructured":"Ghaemmaghami S, May BC, Renslo AR, Prusiner SB. Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol. 2010;84:3408\u201312.","journal-title":"J Virol"},{"key":"1455_CR194","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/jm101250y","volume":"54","author":"A Gallardo-Godoy","year":"2011","unstructured":"Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. 2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem. 2011;54:1010\u201321.","journal-title":"J Med Chem"},{"key":"1455_CR195","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/infdis\/jiu656","volume":"212","author":"D Berry","year":"2015","unstructured":"Berry D, Giles K, Oehler A, Bhardwaj S, DeArmond SJ, Prusiner SB. Use of a 2-aminothiazole to treat chronic wasting disease in transgenic mice. J Infect Dis. 2015;212:S17\u201325.","journal-title":"J Infect Dis"},{"key":"1455_CR196","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.115.224659","volume":"355","author":"K Giles","year":"2015","unstructured":"Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, et al. Different 2-aminothiazole therapeutics produce distinct patterns of scrapie prion neuropathology in mouse brains. J Pharmacol Exp Ther. 2015;355:2\u201312.","journal-title":"J Pharmacol Exp Ther"},{"key":"1455_CR197","first-page":"e1008581","volume":"16","author":"CM Burke","year":"2020","unstructured":"Burke CM, Mark KM, Kun J, Beauchemin KS, Supattapone S. Emergence of prions selectively resistant to combination drug therapy. PLoSPathog. 2020;16:e1008581.","journal-title":"PLoSPathog"},{"key":"1455_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/srep14944","volume":"5","author":"JW Hyeon","year":"2015","unstructured":"Hyeon JW, Choi J, Kim SY, Govindaraj RG, Jam Hwang K, Lee YS, et al. Discovery of novel anti-prion compounds using in silico and in vitro approaches. Sci Rep. 2015;5:14944.","journal-title":"Sci Rep"},{"key":"1455_CR199","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5607\/en.2020.29.1.93","volume":"29","author":"JW Hyeon","year":"2020","unstructured":"Hyeon JW, Noh R, Choi J, Lee SM, Lee YS, An SSA, et al. BMD42-2910, a novel benzoxazole derivative, shows a potent anti-prion activity and prolongs the mean survival in an animal model of prion disease. Exp Neurobiol. 2020;29:93.","journal-title":"Exp Neurobiol"},{"key":"1455_CR200","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1016\/j.ejmech.2011.08.039","volume":"46","author":"T Kimura","year":"2011","unstructured":"Kimura T, Hosokawa-Muto J, Asami K, Murai T, Kuwata K. Synthesis of 9-substituted 2, 3, 4, 9-tetrahydro-1H-carbazole derivatives and evaluation of their anti-prion activity in TSE-infected cells. Eur J Med Chem. 2011;46:5675\u201359.","journal-title":"Eur J Med Chem"},{"key":"1455_CR201","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/cmdc.201300167","volume":"8","author":"T Kimura","year":"2013","unstructured":"Kimura T, Sako T, Siqin Hosokawa\u2010Muto J, Cui YL, Wada Y, Kataoka Y, et al. Synthesis of an 11C-labeled antiprion GN8 derivative and evaluation of its brain uptake by positron emission tomography. ChemMedChem. 2013;8:1035\u20139.","journal-title":"ChemMedChem"},{"key":"1455_CR202","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1074\/jbc.273.6.3484","volume":"273","author":"S Caspi","year":"1998","unstructured":"Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R. The anti-prion activity of Congo red: putative mechanism. J Biol Chem. 1998;273:3484\u20139.","journal-title":"J Biol Chem"},{"key":"1455_CR203","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1128\/jvi.68.4.2135-2141.1994","volume":"68","author":"B Caughey","year":"1994","unstructured":"Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red. J Virol. 1994;68:2135\u201341.","journal-title":"J Virol"},{"key":"1455_CR204","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1471-4159.1992.tb09437.x","volume":"59","author":"B Caughey","year":"1992","unstructured":"Caughey B, Race RE. Potent inhibition of scrapie\u2010associated PrP accumulation by Congo red. J Neurochem. 1992;59:768\u201371.","journal-title":"J Neurochem"},{"key":"1455_CR205","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1128\/jvi.69.1.506-508.1995","volume":"69","author":"L Ingrosso","year":"1995","unstructured":"Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol. 1995;69:506\u20138.","journal-title":"J Virol"},{"key":"1455_CR206","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1099\/0022-1317-81-4-1155","volume":"81","author":"H Rudyk","year":"2000","unstructured":"Rudyk H, Vasiljevic S, Hennion RM, Birkett CR, Hope J, Gilbert IH. Screening congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J Gen Virol. 2000;81:1155\u201364.","journal-title":"J Gen Virol"},{"key":"1455_CR207","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1021\/jm049922t","volume":"47","author":"S Sellarajah","year":"2004","unstructured":"Sellarajah S, Lekishvili T, Bowring C, Thompsett AR, Rudyk H, Birkett CR, et al. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. J Med Chem. 2004;47:5515\u201334.","journal-title":"J Med Chem"},{"key":"1455_CR208","doi-asserted-by":"publisher","first-page":"30221","DOI":"10.1074\/jbc.270.50.30221","volume":"270","author":"SL Shyng","year":"1995","unstructured":"Shyng SL, Lehmann S, Moulder KL, Harris DA. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem. 1995;270:30221\u20139.","journal-title":"J Biol Chem"},{"key":"1455_CR209","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2010213118","volume":"118","author":"R Petrosyan","year":"2021","unstructured":"Petrosyan R, Patra S, Rezajooei N, Garen CR, Woodside MT. Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone. Proc Natl Acad Sci USA 2021;118:e2010213118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR210","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1128\/JVI.78.10.4999-5006.2004","volume":"78","author":"K Doh-Ura","year":"2004","unstructured":"Doh-Ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol. 2004;78:4999\u20135006.","journal-title":"J Virol"},{"key":"1455_CR211","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1083\/jcb.201308028","volume":"204","author":"A Rouvinski","year":"2014","unstructured":"Rouvinski A, Karniely S, Kounin M, Moussa S, Goldberg MD, Warburg G, et al. Live imaging of prions reveals nascent PrPSc in cell-surface, raft-associated amyloid strings and webs. J Cell Biol. 2014;204:423\u201341.","journal-title":"J Cell Biol"},{"key":"1455_CR212","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbrc.2006.08.072","volume":"349","author":"S Yamaguchi","year":"2006","unstructured":"Yamaguchi S, Nishida Y, Sasaki K, Kambara M, Kim CL, Ishiguro N, et al. Inhibition of PrPSc formation by synthetic O-sulfatedglycopyranosides and their polymers. Biochem Biophys Res Commun. 2006;349:485\u201391.","journal-title":"Biochem Biophys Res Commun"},{"key":"1455_CR213","doi-asserted-by":"publisher","first-page":"e106516","DOI":"10.1371\/journal.pone.0106516","volume":"9","author":"T Yamasaki","year":"2014","unstructured":"Yamasaki T, Suzuki A, Hasebe R, Horiuchi M. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells. PLoS One. 2014;9:e106516.","journal-title":"PLoS One"},{"key":"1455_CR214","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/JVI.80.2.596-604.2006","volume":"80","author":"GJ Raymond","year":"2006","unstructured":"Raymond GJ, Olsen EA, Lee KS, Raymond LD, Bryant PK, Baron GS, et al. Inhibition of protease-resistant prion protein formation in a transformed deer cell line infected with chronic wasting disease. J Virol. 2006;80:596\u2013604.","journal-title":"J Virol"},{"key":"1455_CR215","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1468-1331.2008.02108.x","volume":"15","author":"I Bone","year":"2008","unstructured":"Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: An observational study in the UK. Eur J Neurol. 2008;15:458\u201364.","journal-title":"Eur J Neurol"},{"key":"1455_CR216","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1440-1789.2009.01058.x","volume":"29","author":"Y Tsuboi","year":"2009","unstructured":"Tsuboi Y, Doh\u2010ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology. 2009;29:632\u20136.","journal-title":"Neuropathology"},{"key":"1455_CR217","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1440-1789.2011.01245.x","volume":"32","author":"H Honda","year":"2012","unstructured":"Honda H, Sasaki K, Minaki H, Masui K, Suzuki SO, Doh\u2010ura K, et al. Protease\u2010resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Neuropathology. 2012;32:124\u201332.","journal-title":"Neuropathology"},{"key":"1455_CR218","doi-asserted-by":"publisher","first-page":"11195","DOI":"10.1128\/JVI.02559-06","volume":"81","author":"M Prior","year":"2007","unstructured":"Prior M, Lehmann S, Sy MS, Molloy B, McMahon HE. Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J Virol. 2007;81:11195\u2013207.","journal-title":"J Virol"},{"key":"1455_CR219","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.bbagen.2009.07.011","volume":"1790","author":"K McEvoy","year":"2009","unstructured":"McEvoy K, McMahon HE. Antiprion action of new cyclodextrin analogues. Biochim Biophys Acta Gen Subj. 2009;1790:1382\u20136.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"1455_CR220","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.1073\/pnas.0702671104","volume":"104","author":"K Kuwata","year":"2007","unstructured":"Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, et al. Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci USA. 2007;104:11921\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR221","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.bmcl.2010.12.132","volume":"21","author":"T Kimura","year":"2011","unstructured":"Kimura T, Hosokawa-Muto J, Kamatari YO, Kuwata K. Synthesis of GN8 derivatives and evaluation of their antiprion activity in TSE-infected cells. Bioorg Med Chem Lett. 2011;21:1502\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"1455_CR222","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41551-019-0349-8","volume":"3","author":"K Yamaguchi","year":"2019","unstructured":"Yamaguchi K, Kamatari YO, Ono F, Shibata H, Fuse T, Elhelaly AE, et al. A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques. Nat Biomed Eng. 2019;3:206\u201319.","journal-title":"Nat Biomed Eng"},{"key":"1455_CR223","doi-asserted-by":"publisher","first-page":"11742","DOI":"10.3390\/ijms222111742","volume":"22","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama K, Hara H, Chida J, Pasiana AD, Imamura M, Mori T, et al. Ethanolamine is a new anti-prion compound. Int J Mol Sci. 2021;22:11742.","journal-title":"Int J Mol Sci"},{"key":"1455_CR224","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/bs.ircmb.2015.10.001","volume":"321","author":"E Calzada","year":"2016","unstructured":"Calzada E, Onguka O, Claypool SM. Phosphatidylethanolamine metabolism in health and disease. Int Rev Cell Mol Biol. 2016;321:29\u201388.","journal-title":"Int Rev Cell Mol Biol"},{"key":"1455_CR225","doi-asserted-by":"publisher","first-page":"8546","DOI":"10.1073\/pnas.1204498109","volume":"109","author":"NR Deleault","year":"2012","unstructured":"Deleault NR, Piro JR, Walsh DJ, Wang F, Ma J, Geoghegan JC, et al. Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci USA. 2012;109:8546\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR226","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1128\/JVI.02162-16","volume":"91","author":"CE Hoover","year":"2017","unstructured":"Hoover CE, Davenport KA, Henderson DM, Zabel MD, Hoover EA. Endogenous brain lipids inhibit prion amyloid formation in vitro. J Virol. 2017;91:1110\u201328.","journal-title":"J Virol"},{"key":"1455_CR227","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.nbd.2012.06.026","volume":"48","author":"MA Pouladi","year":"2012","unstructured":"Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, et al. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2012;48:282\u20139.","journal-title":"Neurobiol Dis"},{"key":"1455_CR228","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1471-4159.2009.05906.x","volume":"109","author":"A Heiseke","year":"2009","unstructured":"Heiseke A, Aguib Y, Riemer C, Baier M, Sch\u00e4tzl HM. Lithium induces clearance of protease resistant prion protein in prion\u2010infected cells by induction of autophagy. J Neurochem. 2009;109:25\u201334.","journal-title":"J Neurochem"},{"key":"1455_CR229","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1042\/bj20021596","volume":"372","author":"M P\u00e9rez","year":"2003","unstructured":"P\u00e9rez M, Rojo AI, Wandosell F, D\u00edaz-Nido J, Avila J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J. 2003;372:129\u201336.","journal-title":"Biochem J"},{"key":"1455_CR230","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-016-0068-y","volume":"4","author":"M Gitlin","year":"2016","unstructured":"Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4:27.","journal-title":"Int J Bipolar Disord"},{"key":"1455_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0209-4","volume":"8","author":"A Rela\u00f1o-Gin\u00e9s","year":"2018","unstructured":"Rela\u00f1o-Gin\u00e9s A, Lehmann S, Brillaud E, Belondrade M, Casanova D, Hamela C, et al. Lithium as a disease-modifying agent for prion diseases. Transl Psychiatry. 2018;8:63.","journal-title":"Transl Psychiatry"},{"key":"1455_CR232","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 2013;125:795\u2013813.","journal-title":"Acta Neuropathol"},{"key":"1455_CR233","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bcp.2013.12.023","volume":"88","author":"MJ Guerrero-Mu\u00f1oz","year":"2014","unstructured":"Guerrero-Mu\u00f1oz MJ, Castillo-Carranza DL, Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol. 2014;88:468\u201378.","journal-title":"Biochem Pharmacol"},{"key":"1455_CR234","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1021\/acschemneuro.7b00325","volume":"8","author":"D Matthes","year":"2017","unstructured":"Matthes D, Gapsys V, Griesinger C, de Groot BL. Resolving the atomistic modes of Anle138b inhibitory action on peptide oligomer formation. ACS Chem Neurosci. 2017;8:2791\u2013808.","journal-title":"ACS Chem Neurosci"},{"key":"1455_CR235","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1128\/JVI.77.9.5499-5502.2003","volume":"77","author":"B Caughey","year":"2003","unstructured":"Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J, Baron GS. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol. 2003;77:5499\u2013502.","journal-title":"J Virol"},{"key":"1455_CR236","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/j.1471-4159.2007.05105.x","volume":"104","author":"I Hafner\u2010Bratkovi\u010d","year":"2008","unstructured":"Hafner\u2010Bratkovi\u010d I, Ga\u0161per\u0161i\u010d J, \u0160mid LM, Bresjanac M, Jerala R. Curcumin binds to the \u03b1\u2010helical intermediate and to the amyloid form of prion protein\u2013A new mechanism for the inhibition of PrPSc accumulation. J Neurochem. 2008;104:1553\u201364.","journal-title":"J Neurochem"},{"key":"1455_CR237","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/pathogens2030506","volume":"2","author":"CF Lin","year":"2013","unstructured":"Lin CF, Yu KH, Jheng CP, Chung R, Lee CI. Curcumin reduces amyloid fibrillation of prion protein and decreases reactive oxidative stress. Pathogens. 2013;2:506\u201319.","journal-title":"Pathogens"},{"key":"1455_CR238","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/adt.2007.064","volume":"5","author":"BT Kurien","year":"2007","unstructured":"Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 2007;5:567\u201376.","journal-title":"Assay Drug Dev Technol"},{"key":"1455_CR239","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1074\/jbc.M404751200","volume":"280","author":"F Yang","year":"2005","unstructured":"Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280:5892\u2013901.","journal-title":"J Biol Chem"},{"key":"1455_CR240","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6601623","volume":"90","author":"G Garcea","year":"2004","unstructured":"Garcea G, Jones DJL, Singh R, Dennison AR, Farmer PB, Sharma RA, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90:1011\u20135.","journal-title":"Br J Cancer"},{"key":"1455_CR241","doi-asserted-by":"publisher","first-page":"9701","DOI":"10.18632\/oncotarget.3832","volume":"6","author":"JH Lee","year":"2015","unstructured":"Lee JH, Moon JH, Kim SW, Jeong JK, Nazim UM, Lee YJ, et al. EGCG-mediated autophagy flux has a neuroprotection effect via a class III histone deacetylase in primary neuron cells. Oncotarget. 2015;6:9701.","journal-title":"Oncotarget"},{"key":"1455_CR242","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/antiox11040726","volume":"11","author":"K Karagianni","year":"2022","unstructured":"Karagianni K, Pettas S, Kanata E, Lioulia E, Thune K, Schmitz M, et al. Carnosic acid and carnosol display antioxidant and anti-prion properties in in vitro and cell-free models of prion diseases. Antioxidants. 2022;11:726.","journal-title":"Antioxidants"},{"key":"1455_CR243","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/bioinformatics\/btaa918","volume":"37","author":"B Shaker","year":"2021","unstructured":"Shaker B, Yu MS, Song JS, Ahn S, Ryu JY, Oh KS, et al. LightBBB: computational prediction model of blood\u2013brain-barrier penetration based on LightGBM. Bioinformatics. 2021;37:1135\u20139.","journal-title":"Bioinformatics"},{"key":"1455_CR244","volume":"14","author":"T Wu","year":"2019","unstructured":"Wu T, Kwaku OR, Li HZ, Yang CR, Ge LJ, Xu M. Sense ginsenosides from ginsengs: structure-activity relationship in autophagy. Nat Prod Commun. 2019;14:1934578X19858223.","journal-title":"Nat Prod Commun"},{"key":"1455_CR245","doi-asserted-by":"publisher","first-page":"85697","DOI":"10.18632\/oncotarget.13730","volume":"7","author":"JH Moon","year":"2016","unstructured":"Moon JH, Lee JH, Lee YJ, Park SY. Autophagy flux induced by ginsenoside-Rg3 attenuates human prion protein-mediated neurotoxicity and mitochondrial dysfunction. Oncotarget. 2016;7:85697.","journal-title":"Oncotarget"},{"key":"1455_CR246","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jpi.12182","volume":"57","author":"JK Jeong","year":"2014","unstructured":"Jeong JK, Lee JH, Moon JH, Lee YJ, Park SY. Melatonin\u2010mediated \u03b2\u2010catenin activation protects neuron cells against prion protein\u2010induced neurotoxicity. J Pineal Res. 2014;57:427\u201334.","journal-title":"J Pineal Res"},{"key":"1455_CR247","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1600-079X.2012.00980.x","volume":"53","author":"JK Jeong","year":"2012","unstructured":"Jeong JK, Moon MH, Lee YJ, Seol JW, Park SY. Melatonin\u2010induced autophagy protects against human prion protein\u2010mediated neurotoxicity. J Pineal Res. 2012;53:138\u201346.","journal-title":"J Pineal Res"},{"key":"1455_CR248","doi-asserted-by":"publisher","first-page":"11139","DOI":"10.18632\/aging.103328","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhao D, Wu W, Shah SZA, Lai M, Yang D, et al. Melatonin regulates mitochondrial dynamics and alleviates neuron damage in prion diseases. Aging. 2020;12:11139.","journal-title":"Aging"},{"key":"1455_CR249","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/13014","volume":"1","author":"W Bleazard","year":"1999","unstructured":"Bleazard W, McCaffery JM, King EJ, Bale S, Mozdy A, Tieu Q, et al. The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast. Nat Cell Biol. 1999;1:298\u2013304.","journal-title":"Nat Cell Biol"},{"key":"1455_CR250","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0014-5793(02)02985-X","volume":"523","author":"A Olichon","year":"2002","unstructured":"Olichon A, Emorine LJ, Descoins E, Pelloquin L, Brichese L, Gas N, et al. The human dynamin\u2010related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter\u2010membrane space. FEBS Lett. 2002;523:171\u20136.","journal-title":"FEBS Lett"},{"key":"1455_CR251","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/molecules27030705","volume":"27","author":"D Loh","year":"2022","unstructured":"Loh D, Reiter RJ. Melatonin: regulation of prion protein phase separation in cancer multidrug resistance. Molecules. 2022;27:705.","journal-title":"Molecules"},{"key":"1455_CR252","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1016\/j.bmcl.2009.09.074","volume":"20","author":"C Rivi\u00e8re","year":"2010","unstructured":"Rivi\u00e8re C, Papastamoulis Y, Fortin PY, Delchier N, Andriamanarivo S, Waffo-Teguo P, et al. New stilbene dimers against amyloid fibril formation. Bioorg Med Chem Lett. 2010;20:3441\u20133.","journal-title":"Bioorg Med Chem Lett"},{"key":"1455_CR253","doi-asserted-by":"publisher","first-page":"25901","DOI":"10.1039\/D1RA01891D","volume":"11","author":"PR Sirohi","year":"2021","unstructured":"Sirohi PR, Kumari A, Admane N, Somvanshi P, Grover A. The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein. RSC Adv. 2021;11:25901\u201311.","journal-title":"RSC Adv"},{"key":"1455_CR254","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1007\/s12035-015-9464-z","volume":"53","author":"J Wang","year":"2016","unstructured":"Wang J, Zhang BY, Zhang J, Xiao K, Chen LN, Wang H, et al. Treatment of SMB-S15 cells with resveratrol efficiently removes the PrPSc accumulation in vitro and prion infectivity in vivo. Mol Neurobiol. 2016;53:5367\u201376.","journal-title":"Mol Neurobiol"},{"key":"1455_CR255","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s12031-014-0459-4","volume":"55","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang J, Shi Q, Zhang BY, Chen C, Chen LN, et al. Scrapie infection in experimental rodents and SMB-S15 cells decreased the brain endogenous levels and activities of Sirt1. J Mol Neurosci. 2015;55:1022\u201330.","journal-title":"J Mol Neurosci"},{"key":"1455_CR256","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28296-y","volume":"8","author":"K Phadwal","year":"2018","unstructured":"Phadwal K, Kurian D, Salamat MKF, MacRae VE, Diack AB, Manson JC. Spermine increases acetylation of tubulins and facilitates autophagic degradation of prion aggregates. Sci Rep. 2018;8:10004.","journal-title":"Sci Rep"},{"key":"1455_CR257","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1074\/jbc.M609532200","volume":"282","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and \u03b1-synuclein. J Biol Chem. 2007;282:5641\u201352.","journal-title":"J Biol Chem"},{"key":"1455_CR258","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4161\/auto.5.3.7662","volume":"5","author":"Y Aguib","year":"2009","unstructured":"Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Ertmer A, et al. Autophagy induction by trehalose counter-acts cellular prion-infection. Autophagy. 2009;5:361\u20139.","journal-title":"Autophagy"},{"key":"1455_CR259","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bbrc.2008.06.094","volume":"374","author":"F B\u00e9ranger","year":"2008","unstructured":"B\u00e9ranger F, Crozet C, Goldsborough A, Lehmann S. Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochem Biophys Res Commun. 2008;374:44\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1455_CR260","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0749-9","volume":"9","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Yoon YS, Lee SJ. Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis. 2018;9:712.","journal-title":"Cell Death Dis"},{"key":"1455_CR261","doi-asserted-by":"publisher","first-page":"7660","DOI":"10.1128\/JVI.01165-15","volume":"89","author":"LM Cortez","year":"2015","unstructured":"Cortez LM, Campeau J, Norman G, Kalayil M, Van der Merwe J, McKenzie D, et al. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. J Virol. 2015;89:7660\u201372.","journal-title":"J Virol"},{"key":"1455_CR262","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4161\/pri.28938","volume":"8","author":"L Cortez","year":"2014","unstructured":"Cortez L, Sim V. The therapeutic potential of chemical chaperones in protein folding diseases. Prion. 2014;8:197\u2013202.","journal-title":"Prion"},{"key":"1455_CR263","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.3390\/ijms21124274","volume":"21","author":"TK Ahn","year":"2020","unstructured":"Ahn TK, Kim KT, Joshi HP, Park KH, Kyung JW, Choi UY, et al. Therapeutic potential of tauroursodeoxycholic acid for the treatment of osteoporosis. Int J Mol Sci. 2020;21:4274.","journal-title":"Int J Mol Sci"},{"key":"1455_CR264","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/pr9091680","volume":"9","author":"N El Hachlafi","year":"2021","unstructured":"El Hachlafi N, Lakhdar F, Khouchlaa A, Bakrim S, El Omari N, Balahbib A, et al. Health benefits and pharmacological properties of hinokitiol. Processes. 2021;9:1680.","journal-title":"Processes"},{"key":"1455_CR265","first-page":"840487","volume":"2013","author":"T Jayakumar","year":"2013","unstructured":"Jayakumar T, Hsu WH, Yen TL, Luo JY, Kuo YC, Fong TH, et al. Hinokitiol, a natural tropolone derivative, offers neuroprotection from thromboembolic stroke in vivo. J Evid Based Complement Altern Med. 2013;2013:840487.","journal-title":"J Evid Based Complement Altern Med"},{"key":"1455_CR266","doi-asserted-by":"publisher","first-page":"9836","DOI":"10.1073\/pnas.161274798","volume":"98","author":"C Korth","year":"2001","unstructured":"Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR267","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/pathogens7010027","volume":"7","author":"ML Barreca","year":"2018","unstructured":"Barreca ML, Iraci N, Biggi S, Cecchetti V, Biasini E. Pharmacological agents targeting the cellular prion protein. Pathogens. 2018;7:27.","journal-title":"Pathogens"},{"key":"1455_CR268","doi-asserted-by":"publisher","first-page":"e0182589","DOI":"10.1371\/journal.pone.0182589","volume":"12","author":"C Stincardini","year":"2017","unstructured":"Stincardini C, Massignan T, Biggi S, Elezgarai SR, Sangiovanni V, Vanni I, et al. An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein. PLoS One. 2017;12:e0182589.","journal-title":"PLoS One"},{"key":"1455_CR269","doi-asserted-by":"publisher","first-page":"13794","DOI":"10.1128\/JVI.01502-07","volume":"81","author":"S Cronier","year":"2007","unstructured":"Cronier S, Beringue V, Bellon A, Peyrin JM, Laude H. Prion strain-and species-dependent effects of antiprion molecules in primary neuronal cultures. J Virol. 2007;81:13794\u2013800.","journal-title":"J Virol"},{"key":"1455_CR270","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jpba.2005.08.011","volume":"40","author":"F Touil","year":"2006","unstructured":"Touil F, Pratt S, Mutter R, Chen B. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance. J Pharm Biomed Anal. 2006;40:822\u201332.","journal-title":"J Pharm Biomed Anal"},{"key":"1455_CR271","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-021-01162-1","volume":"9","author":"T Ali","year":"2021","unstructured":"Ali T, Hannaoui S, Nemani S, Tahir W, Zemlyankina I, Cherry P, et al. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. Acta Neuropathol Commun. 2021;9:58.","journal-title":"Acta Neuropathol Commun"},{"key":"1455_CR272","doi-asserted-by":"publisher","first-page":"e1981","DOI":"10.1371\/journal.pone.0001981","volume":"3","author":"D Tribouillard-Tanvier","year":"2008","unstructured":"Tribouillard-Tanvier D, B\u00e9ringue V, Desban N, Gug F, Bach S, Voisset C, et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One. 2008;3:e1981.","journal-title":"PLoS One"},{"key":"1455_CR273","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1524-6175.2007.07161.x","volume":"9","author":"DA Sica","year":"2007","unstructured":"Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens. 2007;9:399\u2013405.","journal-title":"J Clin Hypertens"},{"key":"1455_CR274","doi-asserted-by":"publisher","first-page":"212","DOI":"10.2165\/00003495-198326030-00003","volume":"26","author":"B Holmes","year":"1983","unstructured":"Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1983;26:212\u201329.","journal-title":"Drugs"},{"key":"1455_CR275","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/cn5001588","volume":"5","author":"PH Nguyen","year":"2014","unstructured":"Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, et al. Structure\u2013activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost \u03b12-adrenergic receptor agonistic activity. ACS Chem Neurosci. 2014;5:1075\u201382.","journal-title":"ACS Chem Neurosci"},{"key":"1455_CR276","doi-asserted-by":"publisher","first-page":"e8221","DOI":"10.1371\/journal.pone.0008221","volume":"4","author":"C Bate","year":"2009","unstructured":"Bate C, Tayebi M, Diomede L, Salmona M, Williams A. Glimepiride reduces the expression of PrPC, prevents PrPSc formation and protects against prion mediated neurotoxicity. PLoS ONE. 2009;4:e8221.","journal-title":"PLoS ONE"},{"key":"1455_CR277","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-115","volume":"11","author":"V Ingham","year":"2014","unstructured":"Ingham V, Williams A, Bate C. Glimepiride reduces CD14 expression and cytokine secretion from macrophages. J Neuroinflamm. 2014;11:115.","journal-title":"J Neuroinflamm"},{"key":"1455_CR278","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0006-8993(97)00067-X","volume":"754","author":"A Williams","year":"1997","unstructured":"Williams A, Van Dam AM, Ritchie D, Eikelenboom P, Fraser H. Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res. 1997;754:171\u201380.","journal-title":"Brain Res"},{"key":"1455_CR279","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1124\/pr.58.3.7","volume":"58","author":"AA Farooqui","year":"2006","unstructured":"Farooqui AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev. 2006;58:591\u2013620.","journal-title":"Pharmacol Rev"},{"key":"1455_CR280","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/01.LAB.0000074919.08232.A2","volume":"83","author":"C Ryou","year":"2003","unstructured":"Ryou C, Legname G, Peretz D, Craig JC, Baldwin MA, Prusiner SB. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest. 2003;83:837\u201343.","journal-title":"Lab Invest"},{"key":"1455_CR281","doi-asserted-by":"publisher","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","volume":"77","author":"A Barret","year":"2003","unstructured":"Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, et al. Evaluation of quinacrine treatment for prion diseases. J Virol. 2003;77:8462\u20139.","journal-title":"J Virol"},{"key":"1455_CR282","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-53","volume":"4","author":"L Yung","year":"2004","unstructured":"Yung L, Huang Y, Lessard P, Legname G, Lin ET, Baldwin M, et al. Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis. 2004;4:53.","journal-title":"BMC Infect Dis"},{"key":"1455_CR283","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/jm034093h","volume":"46","author":"M Vogtherr","year":"2003","unstructured":"Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem. 2003;46:3563\u20134.","journal-title":"J Med Chem"},{"key":"1455_CR284","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/JVI.78.3.1281-1288.2004","volume":"78","author":"I Murakami-Kubo","year":"2004","unstructured":"Murakami-Kubo I, Doh-ura K, Ishikawa K, Kawatake S, Sasaki K, Kira J, et al. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol. 2004;78:1281\u20138.","journal-title":"J Virol"},{"key":"1455_CR285","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","volume":"8","author":"J Collinge","year":"2009","unstructured":"Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8:334\u201344.","journal-title":"Lancet Neurol"},{"key":"1455_CR286","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","volume":"63","author":"S Haik","year":"2004","unstructured":"Haik S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Laupr\u00eatre N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt\u2013Jakob disease fails to show significant effects. Neurology. 2004;63:2413\u20135.","journal-title":"Neurology"},{"key":"1455_CR287","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1194\/jlr.M073718","volume":"58","author":"V Perrier","year":"2017","unstructured":"Perrier V, Imberdis T, Lafon PA, Cefis M, Wang Y, Huetter E, et al. Plasma cholesterol level determines in vivo prion propagation. J Lipid Res. 2017;58:1950\u201361.","journal-title":"J Lipid Res"},{"key":"1455_CR288","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/WNR.0b013e328058678d","volume":"18","author":"S Kempster","year":"2007","unstructured":"Kempster S, Bate C, Williams A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport. 2007;18:479\u201382.","journal-title":"Neuroreport"},{"key":"1455_CR289","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.bbrc.2006.07.123","volume":"348","author":"SWF Mok","year":"2006","unstructured":"Mok SWF, Thelen KM, Riemer C, Bamme T, G\u00fcltner S, L\u00fctjohann D, et al. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun. 2006;348:697\u2013702.","journal-title":"Biochem Biophys Res Commun"},{"key":"1455_CR290","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/10409238.2018.1458070","volume":"53","author":"A Jeong","year":"2018","unstructured":"Jeong A, Suazo KF, Wood WG, Distefano MD, Li L. Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer\u2019s disease. Crit Rev Biochem Mol Biol. 2018;53:279\u2013310.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"1455_CR291","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/archneur.65.6.762","volume":"65","author":"Y Haviv","year":"2008","unstructured":"Haviv Y, Avrahami D, Ovadia H, Ben-Hur T, Gabizon R, Sharon R. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch Neurol. 2008;65:762\u201375.","journal-title":"Arch Neurol"},{"key":"1455_CR292","doi-asserted-by":"publisher","first-page":"41918","DOI":"10.1074\/jbc.M405652200","volume":"279","author":"A Ertmer","year":"2004","unstructured":"Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem. 2004;279:41918\u201327.","journal-title":"J Biol Chem"},{"key":"1455_CR293","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/sj.leu.2404606","volume":"21","author":"A Ertmer","year":"2007","unstructured":"Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, et al. The anticancer drug imatinib induces cellular autophagy. Leukemia. 2007;21:936\u201342.","journal-title":"Leukemia"},{"key":"1455_CR294","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/13550280701361516","volume":"13","author":"SW Yun","year":"2007","unstructured":"Yun SW, Ertmer A, Flechsig E, Gilch S, Riederer P, Gerlach M, et al. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol. 2007;13:328\u201337.","journal-title":"J Neurovirol"},{"key":"1455_CR295","doi-asserted-by":"publisher","first-page":"13870","DOI":"10.1021\/acsomega.1c01526","volume":"6","author":"D Advani","year":"2021","unstructured":"Advani D, Kumar P. Therapeutic targeting of repurposed anticancer drugs in Alzheimer\u2019s disease: using the multiomics approach. ACS Omega. 2021;6:13870\u201387.","journal-title":"ACS Omega"},{"key":"1455_CR296","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3389\/fbioe.2020.00975","volume":"8","author":"\u00d3 L\u00f3pez-P\u00e9rez","year":"2020","unstructured":"L\u00f3pez-P\u00e9rez \u00d3, Badiola JJ, Bolea R, Ferrer I, Llorens F, Mart\u00edn-Burriel I. An update on autophagy in prion diseases. Front Bioeng Biotechnol. 2020;8:975.","journal-title":"Front Bioeng Biotechnol"},{"key":"1455_CR297","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2165\/00003495-199345040-00007","volume":"45","author":"HA Friedel","year":"1993","unstructured":"Friedel HA, Fitton A. Flupirtine. Drugs. 1993;45:548\u201369.","journal-title":"Drugs"},{"key":"1455_CR298","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1083\/jcb.200711002","volume":"181","author":"H Khosravani","year":"2008","unstructured":"Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Cell Biol. 2008;181:551\u201365.","journal-title":"J Cell Biol"},{"key":"1455_CR299","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/pharmaceutics10040281","volume":"10","author":"MA Patil","year":"2018","unstructured":"Patil MA, Matter BA, Raol YH, Bourne DW, Kelley RA, Kompella UB. Brain distribution and metabolism of flupirtine, a nonopioid analgesic drug with antiseizure effects, in neonatal rats. Pharmaceutics. 2018;10:281.","journal-title":"Pharmaceutics"},{"key":"1455_CR300","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1358\/dot.2002.38.1.660505","volume":"38","author":"HC Schr\u00f6der","year":"2002","unstructured":"Schr\u00f6der HC, M\u00fcller WE. Neuroprotective effect of flupirtine in prion disease. Drugs Today. 2002;38:49.","journal-title":"Drugs Today"},{"key":"1455_CR301","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17770-8","volume":"7","author":"BA Abdulrahman","year":"2017","unstructured":"Abdulrahman BA, Abdelaziz D, Thapa S, Lu L, Jain S, Gilch S, et al. The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions. Sci Rep. 2017;7:17565.","journal-title":"Sci Rep"},{"key":"1455_CR302","first-page":"46","volume":"44","author":"DH Abdelaziz","year":"2019","unstructured":"Abdelaziz DH, Abdulrahman BA, Gilch S, Schatzl HM. Autophagy pathways in the treatment of prion diseases. Curr OpinPharmacol. 2019;44:46\u201352.","journal-title":"Curr OpinPharmacol"},{"key":"1455_CR303","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.vaccine.2006.09.078","volume":"25","author":"D Ishibashi","year":"2007","unstructured":"Ishibashi D, Yamanaka H, Yamaguchi N, Yoshikawa D, Nakamura R, Okimura N, et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine. 2007;25:985\u201392.","journal-title":"Vaccine."},{"key":"1455_CR304","doi-asserted-by":"publisher","first-page":"e4917","DOI":"10.1371\/journal.pone.0004917","volume":"4","author":"MB Rosset","year":"2009","unstructured":"Rosset MB, Sacquin A, Lecollinet S, Chaigneau T, Adam M, Crespeau F, et al. Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie. PLoS One. 2009;4:e4917.","journal-title":"PLoS One"},{"key":"1455_CR305","doi-asserted-by":"publisher","first-page":"14670","DOI":"10.1073\/pnas.0404772101","volume":"101","author":"M Polymenidou","year":"2004","unstructured":"Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci USA. 2004;101:14670\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR306","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.4049\/jimmunol.179.5.2797","volume":"179","author":"G Kaiser-Schulz","year":"2007","unstructured":"Kaiser-Schulz G, Heit A, Quintanilla-Martinez L, Hammerschmidt F, Hess S, Jennen L, et al. Polylactide-coglycolide microspheres coencapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J Immunol. 2007;179:2797\u2013807.","journal-title":"J Immunol"},{"key":"1455_CR307","doi-asserted-by":"publisher","first-page":"e59143","DOI":"10.1371\/journal.pone.0059143","volume":"8","author":"K Xanthopoulos","year":"2013","unstructured":"Xanthopoulos K, Lagoudaki R, Kontana A, Kyratsous C, Panagiotidis C, Grigoriadis N, et al. Immunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanism. PLoS One. 2013;8:e59143.","journal-title":"PLoS One"},{"key":"1455_CR308","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1016\/j.vaccine.2004.11.067","volume":"23","author":"G Magri","year":"2005","unstructured":"Magri G, Clerici M, Dall\u2019Ara P, Biasin M, Caramelli M, Casalone C, et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine. 2005;23:2862\u20138.","journal-title":"Vaccine."},{"key":"1455_CR309","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4049\/jimmunol.181.1.768","volume":"181","author":"A Sacquin","year":"2008","unstructured":"Sacquin A, Bergot AS, Aucouturier P, Bruley-Rosset M. Contribution of antibody and T cell-specific responses to the progression of 139A-scrapie in C57BL\/6 mice immunized with prion protein peptides. J Immunol. 2008;181:768\u201375.","journal-title":"J Immunol"},{"key":"1455_CR310","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neulet.2007.10.015","volume":"429","author":"J Pilon","year":"2007","unstructured":"Pilon J, Loiacono C, Okeson D, Lund S, Vercauteren K, Rhyan J, et al. Anti-prion activity generated by a novel vaccine formulation. Neurosci Lett. 2007;429:161\u20134.","journal-title":"Neurosci Lett"},{"key":"1455_CR311","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(03)00907-8","volume":"350","author":"A Schwarz","year":"2003","unstructured":"Schwarz A, Kr\u00e4tke O, Burwinkel M, Riemer C, Schultz J, Henklein P, et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett. 2003;350:187\u20139.","journal-title":"Neurosci Lett"},{"key":"1455_CR312","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1099\/vir.0.005041-0","volume":"90","author":"M Tayebi","year":"2009","unstructured":"Tayebi M, Collinge J, Hawke S. Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J Gen Virol. 2009;90:777\u201382.","journal-title":"J Gen Virol"},{"key":"1455_CR313","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/19336896.2017.1367083","volume":"11","author":"R Taschuk","year":"2017","unstructured":"Taschuk R, Scruten E, Woodbury M, Cashman N, Potter A, Griebel P, et al. Induction of PrPSc-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease. Prion. 2017;11:368\u201380.","journal-title":"Prion."},{"key":"1455_CR314","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1016\/j.vaccine.2018.10.057","volume":"36","author":"ME Wood","year":"2018","unstructured":"Wood ME, Griebel P, Huizenga ML, Lockwood S, Hansen C, Potter A, et al. Accelerated onset of chronic wasting disease in elk (Cervus canadensis) vaccinated with a PrPSc-specific vaccine and housed in a prion contaminated environment. Vaccine. 2018;36:7737\u201343.","journal-title":"Vaccine."},{"key":"1455_CR315","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.vaccine.2009.10.134","volume":"28","author":"PD Hedlin","year":"2010","unstructured":"Hedlin PD, Cashman NR, Li L, Gupta J, Babiuk LA, Potter AA, et al. Design and delivery of a cryptic PrPC epitope for induction of PrPSc-specific antibody responses. Vaccine. 2010;28:981\u20138.","journal-title":"Vaccine."},{"key":"1455_CR316","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/dna.2009.0940","volume":"29","author":"C Alexandrenne","year":"2010","unstructured":"Alexandrenne C, Wijkhuisen A, Dkhissi F, Hanoux V, Priam F, Allard B, et al. Electrotransfer of cDNA coding for a heterologous prion protein generates autoantibodies against native murine prion protein in wild-type mice. DNA Cell Biol. 2010;29:121\u201331.","journal-title":"DNA Cell Biol"},{"key":"1455_CR317","doi-asserted-by":"publisher","first-page":"9970","DOI":"10.1128\/JVI.01210-06","volume":"80","author":"N Fernandez-Borges","year":"2006","unstructured":"Fernandez-Borges N, Brun A, Whitton JL, Parra B, Diaz-San Segundo F, Salguero FJ, et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol. 2006;80:9970\u201376.","journal-title":"J Virol"},{"key":"1455_CR318","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.vetmic.2007.03.032","volume":"123","author":"C Nitschke","year":"2007","unstructured":"Nitschke C, Flechsig E, Van den Brandt J, Lindner N, L\u00fchrs T, Dittmer U, et al. Immunisation strategies against prion diseases: Prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie. Vet Microbiol. 2007;123:367\u201376.","journal-title":"Vet Microbiol"},{"key":"1455_CR319","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.neuroscience.2008.02.051","volume":"153","author":"F Go\u00f1i","year":"2008","unstructured":"Go\u00f1i F, Prelli F, Schreiber F, Scholtzova H, Chung E, Kascsak R, et al. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience. 2008;153:679\u201386.","journal-title":"Neuroscience."},{"key":"1455_CR320","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.vaccine.2014.11.035","volume":"33","author":"F Go\u00f1i","year":"2015","unstructured":"Go\u00f1i F, Mathiason CK, Yim L, Wong K, Hayes-Klug J, Nalls A, et al. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine. 2015;33:726\u201333.","journal-title":"Vaccine."},{"key":"1455_CR321","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1128\/JVI.02467-10","volume":"85","author":"B Petsch","year":"2011","unstructured":"Petsch B, M\u00fcller-Schiffmann A, Lehle A, Zirdum E, Prikulis I, Kuhn F, et al. Biological effects and use of PrPSc-and PrP-specific antibodies generated by immunization with purified full-length native mouse prions. J Virol. 2011;85:4538\u201346.","journal-title":"J Virol"},{"key":"1455_CR322","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.mt.6300387","volume":"16","author":"CA Wuertzer","year":"2008","unstructured":"Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther. 2008;16:481\u20136.","journal-title":"Mol Ther"},{"key":"1455_CR323","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4161\/pri.20197","volume":"6","author":"F Moda","year":"2012","unstructured":"Moda F, Vimercati C, Campagnani I, Ruggerone M, Giaccone G, Morbin M, et al. Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice. Prion. 2012;6:383\u201390.","journal-title":"Prion."},{"key":"1455_CR324","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nature01457","volume":"422","author":"AR White","year":"2003","unstructured":"White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 2003;422:80\u20133.","journal-title":"Nature."},{"key":"1455_CR325","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1126\/science.1063093","volume":"294","author":"FL Heppner","year":"2001","unstructured":"Heppner FL, Musahl C, Arrighi I, Klein MA, R\u00fclicke T, Oesch B, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 2001;294:178\u201382.","journal-title":"Science."},{"key":"1455_CR326","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0304-3940(02)01192-8","volume":"336","author":"EM Sigurdsson","year":"2003","unstructured":"Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett. 2003;336:185\u20137.","journal-title":"Neurosci Lett"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01455-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01455-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01455-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:04:21Z","timestamp":1747911861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01455-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":326,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1038\/s41401-024-01455-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}